AstraZeneca and SOPHiA GENETICS Expand Partnership to Improve Breast Cancer Outcomes Using AI

SOPHiA GENETICS is expanding its partnership with AstraZeneca to improve breast cancer patient outcomes using AI. The collaboration will leverage SOPHiA GENETICS' multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. AstraZeneca will also develop a bespoke AI-powered predictive model to optimize outcomes for individuals undergoing treatment for breast cancer. The partnership reinforces SOPHiA GENETICS' position as a trusted technology partner and underlines its commitment to advancing global health through federated data analytics and artificial intelligence.

In a significant development for the healthcare sector, SOPHiA GENETICS has announced an expanded partnership with AstraZeneca to leverage artificial intelligence (AI) for improving breast cancer patient outcomes. The collaboration, which involves the use of SOPHiA GENETICS' multimodal AI Factories, aims to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer [1].

The partnership will also facilitate the development of a bespoke AI-powered predictive model aimed at optimizing outcomes for individuals undergoing treatment for breast cancer. This initiative underscores the growing demand for secure, compliant, and scalable real-world AI applications in the healthcare sector [1].

SOPHiA GENETICS, a cloud-native healthcare technology company, specializes in data-driven medicine and is known for its AI Factories, which offer powerful predictive insights through the analysis of complex genomic and multimodal data. AstraZeneca, a global biopharmaceutical company, will utilize these AI Factories to analyze healthcare data, including genomics, imaging, and clinical data, to generate AI-powered insights for optimizing breast cancer outcomes [1].

The collaboration will also involve real-world evidence generation in Europe and North America, with the goal of uncovering key drivers of treatment efficacy and addressing critical knowledge gaps. This will ultimately enhance clinical decision-making through deeper insights, thereby improving patient outcomes [1].

Ross Muken, President of SOPHiA GENETICS, expressed pride in deepening the partnership with AstraZeneca, highlighting the platform's ability to manage complex healthcare data environments. He emphasized the shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI [1].

Jorge Reis-Filho, Chief AI and Data Scientist at AstraZeneca, underscored the company's AI strategy in oncology clinical development, stating that the collaboration will help generate a more holistic understanding of disease biology and biomarkers to tailor effective treatments to patients living with cancer [1].

This partnership reinforces SOPHiA GENETICS' position as a trusted technology partner and underlines its commitment to advancing global health through federated data analytics and artificial intelligence [1].

References:
[1] https://www.newswire.ca/news-releases/sophia-genetics-expands-collaboration-with-astrazeneca-using-ai-to-improve-breast-cancer-patient-outcomes-888115830.html